Interferon alfa-2b alone or combined with recombinant granulocyte-macrophage colony-stimulating factor as treatment of chronic hepatitis C

Scandinavian Journal of Gastroenterology

Volumn 37, Issue 7, 2002, Pages 840-844

  Gronbaek K ^a   Krarup, H Bygum ^a   Ring Larsen, H ^a   Schaffalitzky de Muckadell, O ^a   Moller A ^a   Schlichting, P ^a   Vyberg, M ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Chronic hepatitis C; Granulocyte macrophage colony stimulating factor

Indexed keywords

ALANINE AMINOTRANSFERASE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ALPHA2B INTERFERON; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BEHAVIOR DISORDER; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; FEMALE; FEVER; FIBROSIS; FOLLOW UP; GENOTYPE; HAIR LOSS; HEADACHE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IRRITABILITY; LEUKOCYTE COUNT; LIVER BIOPSY; MALE; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THYROID DISEASE; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD; BIOASSAY; BIOPSY; COMPARATIVE STUDY; DRUG COMBINATION; HEPATITIS C VIRUS; ISOLATION AND PURIFICATION; LIVER; LIVER FUNCTION TEST; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; VIROLOGY;

ADULT; AGED; BIOPSY; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RNA, VIRAL; TREATMENT OUTCOME; VIREMIA;

EID: 4243296511     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/gas.37.7.840.844     Document Type: Article

References (18)

1. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis
2. Natural course of chronic hepatitis C
3. Natural history of liver fibrosis progression in patients with chronic hepatitis C
4. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
5. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic hepatitis infection with hepatitis C virus
6. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C
7. Granulocyte-macrophage colony-stimulating factor: Pleotropic cytokine with potential clinical usefulness
8. Physiology of granulocyte and macrophage colony-stimulating factor in host defense
9. Molecular physiology of granulocyte macrophage colony-stimulating factor
10. Granulocyte-macrophage colony-stimulating factor: More than hemopoietin
11. A quantitative HCV-PCR test for routine diagnostics
12. Interferon-α2b therapy in low-activity hepatitis C: A pilot study
13. Haemophilic patients with hepatitis C have higher viral load compared to other well-defined patient groups
14. An algorithm for the grading of activity in chronic hepatitis C
15. Pilot study of recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of chronic hepatitis B
16. Randomized controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor for the treatment of chronic hepatitis C
17. Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C
18. Granulocyte-macrophage colony-stimulating factor as adjuvant therapy for interferon α treatment of chronic hepatitis C